About
Cell Therapy
Areas of Focus
Categories
Stem Cell & Cellular TherapySouthwestern U.S.
Team (10)
Cliona M. Rooney, PH.D.
Cliona M. Rooney, PH.D.
Marker Therapeutics
team_member
David Eansor
David Eansor
Marker Therapeutics
team_member
Edmund Cheung
Edmund Cheung
Marker Therapeutics
team_member
Helen E. Heslop, M.D., D.SC. (HON)
Helen E. Heslop, M.D., D.SC. (HON)
Marker Therapeutics
team_member
Juan F. Vera, M.D.
Juan F. Vera, M.D.
Marker Therapeutics
team_member
Katharine Knobil, M.D.
Katharine Knobil, M.D.
Marker Therapeutics
team_member
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
7
As Collaborator
2
Total Enrollment
554
By Phase
PHASE1: 4PHASE2: 4NA: 1
By Status
COMPLETED: 5RECRUITING: 2NOT_YET_RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06552416Lead Sponsor
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
PHASE1Recruiting
40 participants
Started: Jun 16, 2025 · Completed: Sep 30, 2029
NCT06549751Lead Sponsor
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
PHASE1Not yet recruiting
30 participants
Started: Sep 30, 2024 · Completed: Dec 31, 2027
NCT05798897Lead Sponsor
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
PHASE1Recruiting
79 participants
Started: Jan 2, 2023 · Completed: Feb 28, 2028
NCT04511130Lead Sponsor
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
PHASE2Completed
47 participants
Started: Oct 14, 2020 · Completed: Mar 1, 2024
NCT04358003Lead Sponsor
Plasma Adsorption in Patients With Confirmed COVID-19
NACompleted
107 participants
Started: May 20, 2020 · Completed: Apr 1, 2022
Locations (1)
Headquarters
Houston, TX, United States
Map
Loading map...